Abstract：Objective To understand the current situation and development trend of the adjuvant drug injections in Changshu NO.1 People′s Hospital (“our hospital” for short), so as to provide reference for clinical rational use of the drugs. Methods According to the key monitoring directory of adjuvant drug injections issued by Suzhou and Nanjing Health and Family Planning Commission of Jiangsu Province, the relevant data of adjuvant drug injection from 2014 to 2016 was collected from HIS. The consumption sum, annual growth rate, defined daily dose system (DDDs), sorting ratio and defined daily cost (DDC) of the adjuvant drug injections were statistically analyzed according to the limited daily dose recommend to WHO. Results During 3 years, the consumption sum of adjuvant drug injections each were 70.8482, 63.5041 and 49.8739 million yuan. The consumption sum of adjuvant drug injections of 2015 and 2016 declined by 10.37% and 21.46% compared with last year. The proportion of consumption sum of adjuvant drug injections in all drugs were 19.64% in 2014, 16.52% in 2015 and 12.94% in 2016. The first and second categories of consumption sum and DDDs rank were neurological drugs and immunomodulating drugs. The top 3 varieties of single item of consumption sum were ganglioside, mouse nerve growth factor and Edaravone. The top 3 varieties of single item of DDDs were lentinan, fat-soluble vitamin (Ⅱ) and Alprostadil. Conclusion The use of adjuvant drug injections in our hospital has dropped drastically, and the effectiveness of management and control is remarkable. However, it still needs to focus on the adjuvant drugs with poor cost performance to further promote their rational use.
王建 张桂芬 支文煜 卢虹 朱爱国. 我院2014～2016年辅助用药注射剂使用分析[J]. 中国医药导报, 2018, 15(2): 127-131.
WANG Jian ZHANG Guifen ZHI Wenyu LU Hong ZHU Aiguo. Analysis of the utilization of adjuvant drug injections from 2014 to 2016 in our hospital. 中国医药导报, 2018, 15(2): 127-131.
京公网安备 11010502046598号